What is the 13F Pro Quality Score for BIVI?

13F Pro ranks BIOVIE INC. (BIVI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BIVI's current score at https://13fpro.ai/research/BIVI (free sign-up required for the full ranking).

Which hedge funds own the most BIVI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BIVI include Diametric Capital,, Diametric Capital,, ARMISTICE CAPITAL,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BIVI as soon as new 13F filings post.

Where does 13F Pro source BIVI data?

All BIOVIE INC. fundamentals and ownership data come directly from SEC EDGAR. BIOVIE INC. files with the SEC under CIK 1580149. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BIVI in?

BIOVIE INC. (BIVI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BIVI research updated on 13F Pro?

BIVI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIOVIE INC.(BIVI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1580149 BIVI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BIVI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIOVIE INC. (BIVI), a Healthcare sector company. BIVI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), BIOVIE INC. reports net income of $-5.3M, free cash flow of $-7.4M. Top institutional holders of BIVI by reported 13-F value include Diametric Capital,, Diametric Capital,, ARMISTICE CAPITAL,, based on the most recent SEC filings. BIVI trades on the Nasdaq exchange and files with the SEC under CIK 1580149. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIVI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOVIE INC. directly from SEC EDGAR.

Net Income

Q3 2026

$-5.3M

Free Cash Flow

Q3 2026

$-7.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+36.1% YoY

$-32.1MFY 2024

FY20 $-16.7MFY22 $-26.1MFY23 $-50.3MFY24 $-32.1M

Operating Income

+28.6% YoY

$-32.2MFY 2024

FY20 $-2.7MFY22 $-27.3MFY23 $-45.1MFY24 $-32.2M

EPS (Diluted)

-372.2% YoY

$-5.62FY 2024

FY20 $-5.23FY22 $-0.81FY23 $-1.19FY24 $-5.62

Total Assets

-28.2% YoY

$25.2MFY 2024

FY20 $2.1MFY22 $20.1MFY23 $35.1MFY24 $25.2M

Total Debt

—FY 2024

FY20 $62.5KFY22 —FY23 —FY24 —

Op. Cash Flow

+30.6% YoY

$-27.9MFY 2024

FY20 $-1.6MFY22 $-19.0MFY23 $-40.3MFY24 $-27.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2020	FY 2018	FY 2017
Net Income	$-32.1M +36.1%	$-50.3M -92.7%	$-26.1M -56.4%	$-16.7M -585.1%	$-2.4M -82.9%	$-1.3M
Operating Income	$-32.2M +28.6%	$-45.1M -65.4%	$-27.3M -912.0%	$-2.7M -13.5%	$-2.4M -52.7%	$-1.6M
EPS (Diluted)	$-5.62 -372.2%	$-1.19 -47.1%	$-0.81 +84.5%	$-5.23	—	—
Total Assets	$25.2M -28.2%	$35.1M +74.5%	$20.1M +865.2%	$2.1M -4.2%	$2.2M -8.0%	$2.4M
Total Debt	—	—	—	$62.5K	—	—
Operating Cash Flow	$-27.9M +30.6%	$-40.3M -112.0%	$-19.0M -1066.4%	$-1.6M -162.1%	$-621.3K +0.4%	$-623.6K

AI Insight: BIVI Financial Trends

BioVie burns cash every quarter with no reported revenue — operating losses persist and equity has eroded from $25M to $16M since Q3 2025.

• Operating income has been negative every quarter, widening from -$3M in Q1 2025 to -$6M in Q4 2025.

• Operating cash flow deteriorated sharply to -$7M in Q1 2026, the worst level in the observed period.

• Equity declined from $25M in Q3 2025 to $16M in Q1 2026, a $9M contraction in two quarters.

⚠ No revenue reported across all eight quarters — any first revenue recognition would be a critical inflection point.

⚠ Equity at $16M and accelerating cash burn of -$7M in Q1 2026 raises near-term funding risk.

AI Insight: BIVI Ratio Trends

BIVI's profitability metrics remain deeply negative with extreme quarter-to-quarter swings, signaling an unpredictable, pre-commercial-stage financial profile.

• ROE swung from -118.1% in Q3 2024 to 79.3% in Q1 2025, then collapsed to -81.7% in Q3 2025 — no sustained recovery visible.

• ROIC deteriorated from -54.8% in Q1 2025 to -84.8% in Q3 2025, suggesting worsening capital efficiency over that stretch.

• Q1 2026 ROE of 20.5% and ROA of 18.2% represent the strongest readings in the dataset, though TTM ROE of -128.3% signals these are likely one-off.

⚠ TTM ROE of -128.3% versus Q1 2026's 20.5% — a sharp divergence suggesting a one-time gain rather than structural improvement.

⚠ OpMargin and NPM are absent across all periods; inability to measure core earnings quality is a material analytical gap.

⚠ D/E data is entirely missing — leverage profile is unobservable, leaving balance sheet risk unquantifiable.

Get alerted when BIVI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIOVIE INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BIVI

Diametric Capital, LP
$518.0K370,000 sh
Diametric Capital, LP
$232.5K750,000 sh
ARMISTICE CAPITAL, LLC
$155.0K500,000 sh
Warberg Asset Management LLC
$141.6K456,629 sh
PRELUDE CAPITAL MANAGEMENT, LLC
$128.9K92,063 sh
GEODE CAPITAL MANAGEMENT, LLC
$117.9K84,203 sh
VANGUARD CAPITAL MANAGEMENT LLC
$117.7K84,067 sh
MORGAN STANLEY
$105.3K75,221 sh
RENAISSANCE TECHNOLOGIES LLC
$95.1K67,918 sh
CITADEL ADVISORS LLC
$63.4K45,292 sh

Fund	Value	Shares
Diametric Capital, LP	$518.0K	370,000
Diametric Capital, LP	$232.5K	750,000
ARMISTICE CAPITAL, LLC	$155.0K	500,000
Warberg Asset Management LLC	$141.6K	456,629
PRELUDE CAPITAL MANAGEMENT, LLC	$128.9K	92,063
GEODE CAPITAL MANAGEMENT, LLC	$117.9K	84,203
VANGUARD CAPITAL MANAGEMENT LLC	$117.7K	84,067
MORGAN STANLEY	$105.3K	75,221
RENAISSANCE TECHNOLOGIES LLC	$95.1K	67,918
CITADEL ADVISORS LLC	$63.4K	45,292

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BIVI on your watchlist

Track score changes the day BIOVIE INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BIVI a good stock to buy?

13F Pro's AI-powered analysis of BIOVIE INC. (BIVI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIVI are available on the BIVI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BIVI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIVI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOVIE INC.'s investment landscape.